6 completed, 4 not yet recruiting, 3 recruiting, 2 unknown. 7 Phase 2, 5 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Stiff-Person Syndrome: new trials by email Literature Review of Stiff-Person Syndrome trials Research Report on Stiff-Person Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome Kedrion IVIg 10%, Human Albumin - Stiff Person Syndrome | Phase 3 | Not yet recruiting | Kedrion S.p.A. | 38 | 2026-11-01 | 2026-10-22 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS) VYVGART Hytrulo, Hytrulo-placebo (consisting of Hyaluronidase) - Stiff Person Syndrome | Phase 2 / Phase 3 | Recruiting | Thomas Jefferson University | 26 | 2026-09-30 | 2026-10-06 |
| Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study) Extracorporeal photopheresis (ECP) - Stiff Person Syndrome | Early Phase 1 | Withdrawn | Yandy Marx Castillo Aleman | 2026-08-01 | 2026-08-06 | |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 KYV-101 - Refractory Lupus Nephritis, Myasthaenia Gravis | Recruiting | Kyverna Therapeutics | 70 | 2025-11-24 | 2026-02-11 | |
| Efgartigimod for Stiff Person Syndrome (ESPS) Efgartigimod - Stiff-Person Syndrome | Phase 2 | Not yet recruiting | University of South Florida | 10 | 2025-04-01 | 2025-04-11 |
| A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease ADI-001, Fludarabine, Cyclophosphamide - Lupus Nephritis, Autoimmune Diseases | Phase 1 | Enrolling by invitation | Adicet Therapeutics | 180 | 2024-11-10 | 2026-03-19 |
| Evaluating Spinal Cord Stimulation for Stiff Person Syndrome SCS trial lead - Stiff-Person Syndrome | Not applicable | Completed | Wake Forest University Health Sciences | 2 | 2024-11-01 | 2026-08-31 |
| KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome Standard lymphodepletion regimen - Stiff-Person Syndrome, SPS | Phase 2 | Completed | Kyverna Therapeutics | 27 | 2024-09-25 | 2026-07-24 |
| Biomarkers in Autoimmune Disease of Nervous System biomaker levels - Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder | Recruiting | Tongji Hospital | 50000 | 2024-07-31 | 2026-07-29 | |
| Baby Detect : Genomic Newborn Screening Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 | Completed | Centre Hospitalier Universitaire de Liege | 6824 | 2022-09-01 | 2025-08-12 | |
| HLA Analysis in Autoimmune Encephalitis and Related Disorders Autoimmune Encephalitis, Imbic Encephalitis | Unknown | Hospices Civils de Lyon | 160 | 2019-10-01 | 2019-09-27 | |
| Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS) HyQvia - Stiff-Person Syndrome | Unknown | Thomas Jefferson University | 22 | 2019-06-01 | 2019-05-14 | |
| Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome Intravenous Immunoglobulins, Human, Placebos - Stiff-Person Syndrome | Phase 3 | Withdrawn | Mayo Clinic | 2018-12-07 | 2019-06-13 | |
| Stem Cell Transplantation for Stiff Person Syndrome (SPS) Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna - Stiff-Person Syndrome | Phase 1 / Phase 2 | Terminated | Northwestern University | 23 | 2014-10-01 | 2021-01-27 |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Autoimmune Disease, Neurologic Autoimmune Disease | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2008-06-01 | 2026-02-27 |
| Rituximab to Treat Stiff Person Syndrome Rituximab, rituximab or placebo - Stiff Person Syndrome | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2004-09-01 | 2011-08-31 |
| Cause, Development, and Progression of Stiff-Person Syndrome Stiff-Person Syndrome | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2002-02-11 | 2017-07-02 | |
| Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS) IVIg - Muscle Rigidity, Spasm | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 20 | 1996-04-01 | 2006-07-14 |
Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Neuromyelitis Optica (4) · Multiple Sclerosis (3) · Lupus Nephritis (2) · Myasthenia Gravis (2) · Myositis (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Scleroderma, Systemic (2) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1) · 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 Deficiency (1) · Acidemia, isovaleric (1) · Acyl-CoA Dehydrogenase Family, Member 9, Deficiency of (1) · Adrenal Hyperplasia, Congenital (1)
Central Nervous System Diseases (20) · Immune System Diseases (20) · Neuromuscular Diseases (20) · Spinal Cord Diseases (20) · Nervous System Diseases (19) · Autoimmune Diseases (15) · Autoimmune Diseases of the Nervous System (15) · Demyelinating Diseases (6) · Demyelinating Autoimmune Diseases, CNS (5) · Eye Diseases (5) · Musculoskeletal Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Cranial Nerve Diseases (4) · Disease Attributes (4)
Cyclophosphamide (3) · Immunoglobulins, Intravenous (2) · Rituximab (2) · fludarabine (2) · thymoglobulin (2) · Antilymphocyte Serum (1) · Carmustine (1) · Cytarabine (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1) · Mesna (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1)
National Institute of Neurological Disorders and Stroke (NINDS) (3) · Kyverna Therapeutics (2) · Thomas Jefferson University (2) · Adicet Therapeutics (1) · CRISPR Therapeutics (1) · Centre Hospitalier Universitaire de Liege (1) · Fred Hutchinson Cancer Center (1) · Hospices Civils de Lyon (1) · Huashan Hospital (1) · Kedrion S.p.A. (1) · Mayo Clinic (1) · Northwestern University (1) · Tongji Hospital (1) · University of South Florida (1) · Wake Forest University Health Sciences (1)
United States (12) · Belgium (1) · China (1) · France (1) · United Arab Emirates (1)
Andrew McKeon, MD (1) · Dai-shi Tian, MD (1) · Janus S Patel, MD (1) · Laurent Servais (1) · Leona Holmberg (1) · Miranda Norton, PhD (1) · Richard Burt, MD (1) · Tuan H Vu, MD (1)
PMID 23568718, PMID 30679041, PMID 33318163, PMID 37479377, PMID 39759515